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Nanoparticle (NP)-based therapeutics promise to significantly improve clinical
medicine in multiple areas by improving target engagement and minimizing off site
effects. To date, most research has focused on tumor models of cancer, aiming to increase
uptake based on the enhanced permeability and retention (EPR) effect. Despite preclinical success and hundreds of proof-of-concept studies, our understanding of the
fundamental interactions between NP and biological systems that govern biological
outcomes remains far from complete. To realize the potential of NPs for cancer
therapeutics, and to expand their application into other diseases that dysregulate the
vasculature, like traumatic brain injury (TBI) and atherosclerosis, the roles
physicochemical properties play in NP uptake must be more fully illuminated. Some
investigations have been performed into the effects of size, surface charge, and various
targeting moieties on uptake into specific tissues and cells, but optimal properties for
uptake vary by application and body region. To investigate the role of different NP
properties on biological outcomes, assessment must be performed that can meaningfully
compare uptake between different NPs. Toward that end, a dynamic contrast-enhanced
magnetic resonance imaging (DCE-MRI) and kinetic modeling protocol was developed
and applied to compare uptake of contrast-enhancing NPs in two animal models, TBI and
atherosclerosis. DCE-MRI compares pre- and post-contrast images to quantify contrast

agent (CA) uptake, in this case NP uptake. In TBI, significantly greater accumulation was
seen in focal injury than in contralateral brain. Uptake was affected by post-injury
administration time in one NP, but no time dependence was seen in a small molecule CA,
suggesting NP properties affect optimal post-injury administration time. In a mouse
model of atherosclerosis, significantly greater NP uptake was detected in plaque regions
than in a contralateral control artery. Plaque phenotype did not affect uptake, but past
studies and NP behavior in other applications suggest modifying NP properties may
result in differential uptake between phenotypes. This thesis describes a method of NP
uptake assessment based on DCE-MRI and kinetic modeling in two animal models.
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CHAPTER 1: INTRODUCTION
1.1 Nanoparticles in medicine

Nanoparticles (NPs) comprise a broad range of nanosized constructs, between

roughly 1 nm and 300 nm in medical contexts, whose physicochemical properties are
distinct from those of the same material in macroscale quantities and can be selectively
varied across a wide range by manipulation of size, shape, chemical composition, and
other characteristics.1-3 A relevant example of differing macro and nanoscale properties is
seen in Fe3O4 iron oxide, which is ferromagnetic as a macroscale solid but
superparamagnetic as a nanocrystal, giving it the ability to be imaged with MRI.4
Because of the high degree of customization offered by NP systems, small sample of
compositions in Figure 1, they offer promise for improvement in diagnosis and treatment
across various areas of medicine though most previous work has focused on cancer.5-8

Figure 1.1 Examples of NP platforms: (a) liposome, (b) polymer-drug conjugate, (c) polymeric NP, (d)
dendrimer, and (e) iron oxide NP. Red dots representing hydrophilic drugs and blue hydrophobic.
Copyright 2008 Wiley.9
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A particularly promising aspect of NP-based therapeutics in cancer is the
enhanced permeability and retention (EPR) effect (Figure 1.2), which describes the
increased accumulation in primary tumors of low molecular weight agents when
incorporated in polymeric complexes larger than 40 kDa that remain in circulation longer
than about 6 hours.10,11 The proposed explanation of the observed accumulation is the
unique, though highly heterogeneous, internal environment of solid tumors, where
vascular density is high, lymphatic drainage is limited, and a high concentration of
permeability enhancing factors widen interendothelial gaps resulting in leaky
vasculature.12,13 Despite the in vitro and in vivo success seen in pre-clinical models,
translation to clinically relevant drug-polymer conjugates has been slow, due in part to an
oversimplification of the EPR effect as well as the complexity and variability of both
tumors and the NP systems being designed.14,15 NP systems still offer promises of
revolutionary gains in therapeutic and sensing applications though significant research
remains to be done to realize those gains, as evidenced by recent findings calling a
portion of our present understanding of NP extravasation out of the vasculature into
question. Sindhwani et al. used an innovative mouse model of cancer to show a vast, and
size-dependent, majority of gold NPs entered into tumors of three different cell lines via
active processes through endothelial cells rather than passively across endothelial gaps,
up to 97% in 50 nm gold NPs.16 The presently held idea of widened endothelial gaps
being the predominant driver of NP extravasation is contradicted by these results,
suggesting our understanding is incomplete and further investigation is needed to
elucidate the processes behind the observed accumulation.
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Figure 1.2 Fluorescence imaging to demonstrate EPR effect in tumor. Comparison of (A) free rhodamine B
with (B) a bovine serum albumin-rhodamine conjugate (67 kDa) shows greater contrast between tumor and
surrounding tissue with the conjugate probe. Copyright 2013 Elsevier.11

The value of NP customizability is in the effect physicochemical properties have
on biological outcomes. Size, shape, and surface chemistry affect NP behavior both on a
whole system and a cellular level. Size affects system-level distribution: NPs with a
hydrodynamic diameter (HD) of <5.5 nm are subject to rapid clearance by the kidneys17
and those with HD >200 nm tend to accumulate in liver and spleen.18 Size also affects
cellular response to NPs with several studies showing maximum uptake using a HD
around 50 nm.19,20 Shape affects cellular uptake with spheres showing the greater uptake
than rods when HD is <100 nm.21 Surface charge affects protein adsorption and
ultimately cellular uptake with positively charged NPs exhibiting more rapid cellular
uptake.21-23 Surface binding of targeting ligands also affects cellular uptake by initiating
receptor-mediated endocytosis19 and has interactive effects with other properties. Binding
affinity of a ligand for example is affected by whether it is bound to a NP and by the HD
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of the NP to which it is bound, with larger NPs showing higher binding affinity, but not
necessarily higher cellular response.19
The complexity of NP and biological systems in isolation, which is further
complicated when the two systems come together, termed nano-bio interactions, creates a
substantial opportunity to deepen our understanding of the scientific foundations of nanobio interactions already established. Better understanding the role NP physicochemical
properties have on biological outcomes will enable NP design optimization. To come to a
fuller understanding of how NPs affect biological systems, continued research efforts
must be directed to more standardized, systematic, and multifaceted testing of NPs in
representative in vitro and in vivo models. An essential part of that continued research
involves the thoughtful incorporation of various imaging modalities during NP
characterization and testing to more fully illuminate and understand the nano-bio
interactions at play.
1.1.1 Nanoparticles in imaging
The range of applications for NPs in imaging is immense due to the
customizability of different physicochemical properties within a single NP. For example,
size and targeting ligands can be varied to affect cellular fate independent of NP
fluorescence. To enable sufficient depth of discussion our focus will be narrower than all
possible imaging applications of NPs, so we focus this section on the integration of NPs
with fluorescence imaging and magnetic resonance imaging (MRI).
Fluorescence imaging is ubiquitous across much of NP design and assessment due
in part to its utility in a multitude of applications, from analysis on the scale of the whole
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organism to the nano-bio interactions occurring within a single cell. When an NP is
administered intravenously, nano-bio interactions begin as soon as the NP is released into
systemic circulation and continue over the lifetime of the NP in the organism. These
interactions form a cascade, with certain events, like adsorption of particular proteins,
prompting subsequent events, like recognition or indifference from the immune system,
based on the first event; interactions beget specific subsequent interactions. Fluorescence
imaging offers the flexibility to visualize portions of these interactions at various
timepoints and size scales within the interwoven network of biological events.
Pre-clinical studies focused on the improvement of NP delivery must address a
great myriad of factors, but one critically important aspect of all NP delivery work is
biodistribution. An understanding of gross NP accumulation on a whole organism level
following administration into the systemic circulation provides valuable preliminary
insight into target engagement and toxicity. Biodistribution is commonly assessed via
near-infrared (NIR) fluorescence imaging, as NIR exciting light readily passes deep into
tissue and endogenous cellular materials exhibit minimal background interference.24 NIR
fluorescence is often achieved with organic fluorophores based on cyanine including
indocyanine green (ICG) though for applications where hydrophobicity is advantageous,
such as in testing of polymeric NPs,25 liposomes,26 micelles,27 and lipid NPs,28 1,1′dioctadecyl-3,3,3′,3′-tetramethylindotricarbo-cyanine iodide (DiR) is utilized (Figure
1.3).24 NIR fluorescence is also produced by some varieties of inorganic quantum dots
(QDs).2 CdTe/CdSe QDs have been used to generate NIR emission from sentinel lymph
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nodes in pigs,29 though toxicity concerns related to heavy metal ions has prompted the
study of other compositions for NIR QDs including Ag2S.30,31

Figure 1.3 Whole body imaging of KB tumor mouse model following injection of NIR NPs at different
DiR loading (0.5 or 3.6%) and NP dose (0.4 or 4 mg). Red circle indicates subcutaneous tumor. Copyright
American Chemical Society 2018.24

While an understanding of biodistribution on the whole organism level is
valuable, it offers limited insight into NP behavior at the cellular level. Fluorescent
probes can still be used but imaging technique must be adjusted to illuminate the nanobio interactions taking place at the cell (Figure 1.4). Confocal microscopy can be used for
localization of NPs on a subcellular level, and in combination with immunostaining NP
location can be described relative to specific cellular components.32,33 Probing further
into NP behavior on the subcellular level is vital to the future of NP research; the
intracellular location of a NP informs understanding on the mechanism(s) of action, or
provides explanation for lack of effect. In cerium oxide NPs, for example, confocal
microscopy showed a relationship between localization within cells and surface-charge,
with positively and negatively-charged NPs colocalizing with lysosomes while neutral
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NPs showed a diffuse distribution throughout the cytoplasm.34 The acidic environment
within lysosomes evokes oxidase activity from cerium oxide NPs, explaining the
increased cytotoxicity seen in charged NPs compared with neutral NPs. Another example
of the utility of subcellular fluorescence imaging is provided in a more complex, pHresponsive NP system for tumor targeting.35 Neutravidin-iminobiotin bonds were
incorporated into synthesis for degradation in low pH environments to expose a positive
surface-charge and encourage endocytosis. Confocal microscopy and immunostaining
served to collocate NPs with hypoxic, and therefore acidic, tumor regions, verifying the
selective increase in uptake sought with the multilayer, degradative approach.

Figure 1.4 Example of confocal microscopy for colocalization of NPs and cellular components. Red,
green, and yellow correspond to NPs, endosome markers, and overlapping signal, respectively. Rab8, 11,
and 14 mark recycling endosomes while EEA1 marks early endosomes. Copyright Future Medicine Ltd
2011.32

In the cases described above fluorescence is more adjunct than essential to the
final desired function of the NP; the benefit of fluorescence is in tracking NP behavior at
both the macro and micro scales to inform future iterations of NP design. Some NP
systems however are designed specifically for imaging in the aid of diagnosis, or for a
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combination of therapeutic effect and diagnostic information, termed theranostic NPs.36-38
Many NPs for imaging applications are inorganic and fall into one of several categories,
QDs, briefly discussed above, metal NPs, metal oxide NPs, and lanthanide-doped
NPs.1,2,39 Imaging applications of inorganic NPs include dark-field microscopy with
surface plasmon resonance,40 computed tomography (CT),41 Raman spectroscopy,42
photoacoustic tomography,43 MRI, etc. Non-invasive in vivo fluorescence imaging is
limited in its scope, as previously mentioned, it can provide information on whole
organism biodistribution but provides little knowledge about NP behavior on the smaller
scale. NP concentrations required for contrast-enhancement in CT are too high to be used
in animal models, though CT is widely clinically available. Raman spectroscopy requires
specialized instruments that are clinically uncommon. MRI enables non-invasive in vivo
visualization of soft-tissues with spatial resolution in the realm of 100 microns per pixel
and temporal resolution of less than 30s depending upon scan parameters. MRI is also
commonly available and utilized in clinical settings.

1.2 MRI

MRI is an imaging modality that uses combinations of fixed magnetic fields and

variable radio frequency (RF) pulses to excite water protons to non-invasively distinguish
tissues, assess water diffusion and other tissue properties, and describe blood flow
characteristics.44 Two key properties that contribute to the signal seen in MR images, and
therefore our ability to assess anatomy and function, are T1 and T2,. T1, longitudinal
relaxation time, describes the rate at which net magnetization in the direction of the static
magnetic field, B0, is recovered following the RF pulse. T2, transverse relaxation time,
describes the rate at which precessing protons fall out of phase with one another
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following the unifying excitation of the RF pulse.44 T1 and T2 are inherent to different
tissues and their variation yields the contrast we see in MRI, with different pulse
sequences accentuating signal related to T1 or T2 (Figure 1.5). Though different tissues
exhibit differing relaxation times contrast agents (CAs) are often employed, in 40-50% of
clinical examinations, to further distinguish tissues.45 CAs in MRI work by shortening T1
and/or T2 of water protons in the tissue(s) of interest, increasing image contrast.6,46 The
change in relaxation rate at a given magnetic field and physiological environment
corresponds to CA concentration and is characterized by relaxivity (r1 or r2 corresponding
to T1 or T2), measured in mM-1s-1 (eq. 1).
�

1

𝑇𝑇1,2

�

𝑜𝑜𝑜𝑜𝑜𝑜

1

= �𝑇𝑇 � + 𝑟𝑟1,2 ⋅ [𝐶𝐶𝐶𝐶]
1,2

0

(1)

where (T1,2)obs is the calculated relaxation rate following contrast administration, (T1,2)0 is
the relaxation rate prior to contrast enhancement, and r1,2 is the relaxivity of the CA.
At present the majority of CAs used in MRI are based on Gadolinium, Gd,
chelates for T1-enhancement, originating with Gd-DTPA, the first commercial MRI
CA.6,45 Small-molecule Gd-chelates, while effective for T1-enhancement, have recently
been called into question due to the possibility of chelate dissociation and Gd ion release
in vivo resulting in nephrogenic systemic fibrosis (NSF), encouraging the development of
a new generation of macromolecular CAs with improved biocompatibility and relaxivity
characteristics. NP-based CAs have been developed and are being refined to create this
next generation of CAs; a particularly well-researched area within the field is iron oxide
NPs (IONPs) for T2-enhancement across a range of HDs, or more recently T1enhancement with HD less than roughly 5 nm.47-49 IONPs are popular due at least in part
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to a variety of established synthesis methods and generally good biocompatibility as iron
naturally occurs within the human system.38,48,50,51 Despite higher r1-values below HD of
5 nm, IONPs still exhibit large r2/r1, the ratio of T2 relaxivity to T1 relaxivity, especially
at high field strength; r2/r1 of 3 nm IONPs at 7T is 11, while Gd-DTPA at the same field
strength is 1.7.47 A high r2/r1 value indicates the CA shortens T2 far more than T1, which
makes images difficult to interpret as T1-shortening results in brighter signal and T2shortening in darker signal.

Figure 1.5 Comparison of T1 and T2-weighted scans of a mouse brain perpendicular to the spinal axis.

The limitations of IONPs for T1-enhancement and the efficacy of small-molecule
Gd-chelates has led others to investigate NP CAs based on Gd including Gd oxide
nanocrystals, protein, polymer, dendrimer, and liposome-based Gd complexes.6 Gd-based
NP CAs show great variety in r1-values and in r2/r1-values, but can be designed to exhibit
similar or superior T1-enhancement to small-molecule Gd-chelate CAs while eliminating
concerns of NSF.3,52 The degree of customization afforded by NP systems allows the
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combining of Gd-based T1-enhancement with therapeutic molecules to non-invasively
visualize NP uptake in specific targets. This combination of therapeutic and diagnostic
aspects, termed theranostic, provides treatment and information on the efficacy of that
treatment to describe the nano-bio interactions taking place. As discussed above, much of
the available data on NP behavior is in the context of cancer, in line with that, previous
research on Gd NP CAs has been primarily focused on assessing uptake into tumors. A
fuller understanding of nano-bio interactions however offers to expand upon current NP
applications to aid in the treatment of other conditions involving disrupted vasculature or
presentation of unique cellular markers, including traumatic brain injury (TBI) and
atherosclerosis.53-56
1.2.1 Dynamic Contrast-Enhanced MRI
NP improvement is generally focused on increasing uptake and retention in a
specific tissue or cell. Within MRI there are many methods of uptake assessment that
cover a broad spectrum in terms of complexity, from direct signal comparison between
raw images to extensive processing and modeling to describe the physiological properties
affecting uptake and retention.57-60 Across the varied methods there is a general
underlying scheme (Figure 1.6): image the desired body region to establish a baseline,
administer CA, during and/or after administration perform one or more scans for
comparison with the baseline. Dynamic contrast-enhanced MRI (DCE-MRI) follows this
scheme, measuring T1-enhancement over time following administration of a CA with
repeated T1-weighted scans. DCE-MRI is widely applied in investigation of tumor
vascularity and blood-brain barrier (BBB) permeability and enables both heuristic signal
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assessment and physiological modeling depending upon the region scanned.61,62 The
present use of DCE-MRI in clinical settings is also advantageous as it creates a potential
continuity with pre-clinical testing performed in NP development. Additionally, noninvasive imaging in clinical testing enables more meaningful interpretation of results,
illuminating the role of delivery in the observed results.14

Figure 1.6 General method of DCE-MRI, baseline scans are performed prior to contrast enhancement,
during and after contrast administration serial acquisitions are performed.

While simpler methods based on direct signal comparison of baseline and postcontrast images have their place, the conclusions they provide are limited. They cannot
be used to determine location of the CA, whether it is confined to the vasculature or has
extravasated out into surrounding tissue, nor can they be used for comparison between
individuals or within an individual between imaging sessions.62-64
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In contrast to non-model analyses, kinetic modeling estimates the underlying
physiological characteristics governing the signal-enhancement observed in the tissue of
interest including blood flow and endothelial permeability.63 The parameter of primary
interest in uptake assessment is Ktrans, the volume transfer coefficient that describes the
rate of CA extravasation from plasma into the extravascular extracellular space (EES) per
volume of tissue.62 Ktrans is a composite parameter affected by both plasma flow Fp and
the permeability-surface area product PS, but high plasma flow and low CA extravasation
make Ktrans a sound approximation of PS.65 Physiological characteristics can be
meaningfully compared between individuals and as model parameters are more directly
tied to physiological characteristics, model parameters allow for comparison between
studies.66 The advantages afforded by kinetic modeling come at the cost of fairly
extensive image processing that is not required by direct signal comparison methods
because MRI signal intensity is not linearly related to CA concentration.64
The first step in the image processing required for DCE-MRI kinetic modeling is
to move from signal intensity to quantifying T1. T1-mapping can be performed with
various techniques including inversion67 and saturation recovery68, though the focus here
will be on the variable flip angle (VFA) method using spoiled gradient recalled echo
(SPGR) images.69,70 The VFA method is the most commonly used technique in preclinical and clinical DCE-MRI because it enables volumetric T1-mapping both pre and
post contrast with high temporal resolution using a standard pulse sequence.61,71 In the
VFA method two or more baseline SPGR scans are performed holding repetition time
(TR) constant while excitation flip angle (FA) is modified.69 Subsequent scans are taken
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using a single FA and can be compared with baseline images to estimate T1 throughout
the imaging session. Signal (SSPGR) from an SPGR scan is described by the following
equation:
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 =

M0 (1−𝐸𝐸1 )𝑠𝑠𝑠𝑠𝑠𝑠α𝑇𝑇
1−𝐸𝐸1 𝑐𝑐𝑐𝑐𝑐𝑐α𝑇𝑇

(2)

where E1 = exp(-TR/T1), αT is transmitted FA, and M0 is a proportionality factor related
to equilibrium longitudinal magnetization. Rearranging into slope-intercept form, y = mx
+ b, provides:
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆
𝑠𝑠𝑠𝑠𝑠𝑠α𝑇𝑇

𝑆𝑆

𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆
= 𝑡𝑡𝑡𝑡𝑡𝑡α
𝐸𝐸1 + M0 (1 − 𝐸𝐸1 )
𝑇𝑇

(3)

showing a linear relationship between SSPGR/sinαT and SSPGR/tanαT described by E1.
Plotting points from at least two SPGR scans and fitting with a line of slope m provides
T1 as:
−𝑇𝑇𝑇𝑇

𝑇𝑇1 = 𝑙𝑙𝑙𝑙(𝑚𝑚)

(4)

Fitting is performed for each voxel in the field of view (FOV) of the baseline images to
generate pre-contrast T1 (T10) maps. Post contrast T1 maps are made using the same
equation in a two FA scenario with the higher FA scan from the baseline being replaced
by the post-contrast scan using the same FA. As contrast-enhancement from CA
concentration is related to 1/T1, see eq. 1, we assign R1 = 1/T1 and use R1 maps at each
time point for simplicity. Comparing R1 maps at two times, t0, pre-contrast, and t,
sometime post-contrast, we calculate concentration (C) at some time t as:
𝐶𝐶(𝑡𝑡) =

R1 (t)–R1 (t0 )
r1

(5)
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where r1 is relaxivity of the CA administered. When baseline T1 maps are made using
more than two FAs, concentration maps can be generated using pre-contrast T1 maps and
a comparison of pre- and post-contrast image signal. Starting with equation (2),
expanding E1, and substituting in equation (1) yields the following:
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 =

M0 𝑠𝑠𝑠𝑠𝑠𝑠α𝑇𝑇 �1−𝑒𝑒 −𝑇𝑇𝑇𝑇(1/𝑇𝑇1𝑡𝑡 + 𝑟𝑟1 ⋅𝐶𝐶𝐶𝐶] �

(6)

1−𝑐𝑐𝑐𝑐𝑐𝑐α𝑇𝑇 𝑒𝑒 −𝑇𝑇𝑇𝑇(1/𝑇𝑇1𝑡𝑡 + 𝑟𝑟1 ⋅[𝐶𝐶𝐶𝐶]

where T1t is T1 at some time t post-contrast. Comparing pre- and post-contrast signal
intensity from images taken using the same FA creates the following ratio:
𝑅𝑅 =

𝑆𝑆𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝

(7)

𝑆𝑆𝑝𝑝𝑝𝑝𝑝𝑝

which substitutes into equation (6) and following algebraic rearrangement yields:
[𝐶𝐶𝐶𝐶] =

−1

𝑟𝑟1

𝑙𝑙𝑙𝑙 �
𝑇𝑇𝑇𝑇

𝑅𝑅𝑒𝑒 𝑇𝑇𝑇𝑇/𝑇𝑇1𝑡𝑡 (𝑒𝑒 𝑇𝑇𝑇𝑇/𝑇𝑇1𝑡𝑡 − 1) − 𝑒𝑒 𝑇𝑇𝑇𝑇/𝑇𝑇1𝑡𝑡 (𝑒𝑒 𝑇𝑇𝑇𝑇/𝑇𝑇1𝑡𝑡 − 𝑐𝑐𝑐𝑐𝑐𝑐𝛼𝛼𝑇𝑇
𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝛼𝛼𝑇𝑇 �𝑒𝑒 𝑇𝑇𝑇𝑇/𝑇𝑇1𝑡𝑡 −1�−�𝑒𝑒 𝑇𝑇𝑇𝑇/𝑇𝑇1𝑡𝑡 −𝑐𝑐𝑐𝑐𝑐𝑐𝛼𝛼𝑇𝑇 �

�

(8)

CA concentration is quantified using the equation above based on pre- and post-contrast
signal intensity and baseline T1 maps. Whether 2 or more FAs are utilized for imaging
and concentration map generation, the resulting maps from each timepoint are then
utilized for kinetic modeling. Kinetic models require CA concentration in the plasma, Cp,
for comparison with tissue concentrations. To achieve this, finding the arterial input
function (AIF), a region is chosen in the imaging FOV that contains a feeding blood
vessel.62 This is the most common method though some alternatives are discussed in
Chapter 2. Once CA concentration is determined in tissue and blood over the duration of
the imaging session, Ktrans can be determined through modeling. Models vary in the
number of free parameters that are fit to concentration data with more complex models
using more free parameters. Commonly used models are the two compartment exchange
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model (2CXM),72 the modified Tofts model,57 the Patlak model,73 and the steady-state
model.65 Figure 1.7 shows the interrelation between these models. Starting with the
simplest, the steady-state model describes a system in which there is no CA transfer to
the EES:
(9)

𝐶𝐶𝑡𝑡 (𝑡𝑡) = 𝑣𝑣𝑝𝑝 𝐶𝐶𝑝𝑝 (𝑡𝑡)

where Ct and Cp are CA concentration in the tissue and plasma respectively, and vp is the
fractional plasma volume. The Patlak model describes a highly perfused twocompartment system in which CA extravasates out of the plasma compartment into the
EES, but no backflux occurs:
𝑡𝑡

𝐶𝐶𝑡𝑡 (𝑡𝑡) = 𝑣𝑣𝑝𝑝 𝐶𝐶𝑝𝑝 (𝑡𝑡) + 𝐾𝐾 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 ∫0 𝐶𝐶𝑝𝑝 (τ)𝑑𝑑τ

(10)

The modified Tofts model is similar to the Patlak, but considers bidirectional transport of
CA between the plasma compartment and EES:
𝑡𝑡

𝐶𝐶𝑡𝑡 (𝑡𝑡) = 𝑣𝑣𝑝𝑝 𝐶𝐶𝑝𝑝 (𝑡𝑡) + 𝐾𝐾 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 ∫0 𝐶𝐶𝑝𝑝 (τ)𝑒𝑒 −�𝐾𝐾

𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 (𝑡𝑡−τ)�/𝑣𝑣
𝑒𝑒

𝑑𝑑τ

(11)

where ve is the fractional interstitial volume.61 The most general is the 2CXM which is
defined by the following system of equations and considers a two-compartment system
with bidirectional CA transport and plasma flow Fp:
𝑣𝑣𝑝𝑝 𝐶𝐶𝑝𝑝′ = 𝐹𝐹𝑝𝑝 𝐶𝐶𝑎𝑎 + 𝑃𝑃𝑃𝑃 𝐶𝐶𝑒𝑒 − �𝐹𝐹𝑝𝑝 + 𝑃𝑃𝑃𝑃�𝐶𝐶𝑝𝑝
𝑣𝑣𝑒𝑒 𝐶𝐶𝑒𝑒′ = 𝑃𝑃𝑃𝑃 𝐶𝐶𝑝𝑝 − 𝑃𝑃𝑃𝑃 𝐶𝐶𝑒𝑒

where Ca and Ce are CA concentration in arterial plasma and EES respectively, PS is
permeability surface area product. The 2CXM yields unique response functions
depending upon the physiological system being modeled while the other models
represent specified scenarios.58,65 Comparisons of the different models in low-

(12)
(13)
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permeability regimes, such as in the brain where the BBB limits CA extravasation, have
shown the Patlak model yields the highest contrast-to-noise ratio and balances model
complexity and goodness of fit.61,62

Figure 1.7 Comparison of four tracer kinetic models. DCE-MRI parameters are fractional plasma volume
vp, fractional interstitial volume ve, plasma flow Fp, and permeability-surface area product PS. Open source
from Elsevier.62

Model assumptions of large Fp and low CA extravasation make Ktrans a sound
estimate of PS.62 Ktrans has been utilized in many studies as a measure of permeability
because by describing underlying physiology it is a better metric to compare between
individuals, timepoints, and acquisition parameters compared with non-model metrics.66
In BBB assessment Ktrans is commonly assessed to describe permeability, most often with
Gd-based small molecule CAs, like Gd-DTPA.61,62,71,74,75 Permeability however is not
solely dependent upon the status of the barrier being traversed, it is also affected by the
agent traversing the barrier. In the kidneys, for example, the semi-permeable glomerular
capillaries rapidly filter out particles smaller than 5.5 nm, that is the barrier allows
passage of particles with a HD of less than 5.5 nm, while prohibiting larger particles.76
Taking this into account Ktrans may be utilized, in a system properly represented by an
adequate model, to describe permeability differences related to different particle
properties, provided barrier statuses are comparable.
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Development of the next generation of NP-based theranostics relies on a better
understanding of the nano-bio interactions taking place to elicit the desired response. By
combining DCE-MRI with NP-based MRI CAs and kinetic modeling, Ktrans can be used
to measure the effects of NP properties on uptake kinetics. Comparing concentrations
across all timepoints following NP administration better describes preferential uptake
than single timepoint metrics, as these metrics are unable to distinguish NP within the
vasculature from NP outside and neglect NP behavior before or after the single snapshot.
In this work DCE-MRI and Ktrans mapping for permeability quantification are applied in
two different pre-clinical mouse models, a controlled cortical impact model of TBI, and a
carotid artery cuff model of atherosclerosis.
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CHAPTER 2: EVALUATING DIFFERENTIAL NANOPARTICLE
ACCUMULATION AND RETENTION KINETICS IN A MOUSE
MODEL OF TRAUMATIC BRAIN INJURY VIA KTRANS
MAPPING WITH MRI
2.1 Introduction

Traumatic brain injury (TBI) is a leading cause of death and disability,

contributing to 30.5% of all injury-related deaths in the U.S. with 1.7 million new cases
annually.77 Immediate biological responses to TBI include inflammation, oxidative stress,
blood-brain barrier (BBB) breakdown, and oedema, which often result in lifelong
physical, cognitive, and psychosocial impairments that can worsen as individuals age.78,79
Current TBI treatments focus on stabilizing the patient, relieving intracranial pressure,
and optimizing cerebral perfusion. There are no neuroprotective therapies that have
improved neurological outcome in a large, multi-centre Phase 3 clinical trial.80,81 Part of
the difficulty in developing effective therapies for TBI is that systemic administration
does not allow for therapeutically significant drug levels to accumulate and be retained in
the brain for effective target engagement.81-83
Because of the difficulty in reaching effective drug concentrations in the brain,
post-injury BBB opening is of particular interest. Some groups have sought to improve
outcomes by minimizing BBB opening following TBI, but the opening also provides an
opportunity for systemically administered drugs or nanoparticles (NPs) to reach and
accumulate in the damaged region.84-86 The degree of BBB opening varies temporally
post-injury, providing a temporary window of opportunity for increased uptake of a
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therapeutic into the injury.87 Reports of the time of maximum uptake have varied
depending upon the agent being used, suggesting different therapeutic agents optimally
cross the disrupted BBB at different times post-injury.87,88 Thus, it is essential to describe
the time-dependent permeability to any therapeutic agent so that it can be administered at
the opportune time.
NPs represent a highly controllable method of drug delivery, as they can be
designed to regulate release characteristics, their size can be controlled to control
pharmacokinetics and biodistribution, and surface conjugation of targeting agents allows
for attachment to specific sites in the body.89,90 For TBI, the size of NPs can be optimized
to allow rapid accumulation in the damaged tissue, like a small molecule drug, while still
being large enough to be retained in the tissue, not diffusing away as quickly as smaller
molecules.91 This results in a phenomenon similar to the enhanced permeability and
retention (EPR) effect seen in tumors.54,92 Indeed, NPs have gained significant interest in
a number of pre-clinical studies targeting brain injury.86,93-95 Surface modifications can
further increase blood retention time and allow for real-time imaging during
administration.96
The ability to track NP distribution kinetics will help accelerate the discovery of
lead formulations and provide opportunity for tracking efficacy in the clinic. Through the
incorporation of fluorophores and magnetic resonance imaging (MRI) contrast agents
(CAs), NP accumulation can be detected and quantified. One recent NP study used
fluorophores to corroborate the transient nature of TBI-related BBB dysfunction53
previously shown using Evans blue and horseradish peroxidase.87 While accumulation of
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fluorescent NPs can be detected using confocal microscopy, the number of animals
required for sufficient temporal resolution is high especially when correlating with
therapeutic efficacy. In MRI however, sufficient temporal resolution can be achieved in
each individual animal dependent upon the sampling rate. MRI can be used to collect a
dynamic series of images after injection of contrast agent (CA) to determine CA
concentration at each time point. MRI also offers the advantages of describing immediate
uptake of NPs and allowing for multiple imaging sessions from the same animal to enable
assessment of NP uptake, retention, and BBB permeability over an extended time period.
Multiple kinetic models have been created to describe the underlying physiology
that governs the movement of substances from the blood into surrounding tissue.59 The
modified Toft’s model (eq 11) is a commonly utilized two-compartment model that
describes transport between the plasma and interstitial space in a highly perfused tissue
through three parameters, the fractional plasma volume vp, the fractional extravascularextracellular volume ve, and the volume transfer coefficient Ktrans.62 Ktrans has previously
been used to describe BBB permeability in humans and in rats71,74,75,97,98 with MRI as
well as computed tomography (CT).99 Ktrans is the main parameter of interest when
seeking to describe BBB function as it quantifies the rate at which molecules in the
plasma space are transferred to the extravascular-extracellular space and is calculated
based on the relation between CA concentrations in tissue and plasma over time.61 Ktrans
is not solely dependent upon the barrier being traversed, in this case BBB compromised
by a TBI, but also depends on the CA crossing that barrier. Because larger Ktrans values
are to be expected than in a healthy brain, due to BBB disruption following TBI, and the
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lack of feeding arteries visible in the FOV, a variation of the modified Tofts model is
used instead of the Patlak model.
In this work we extend the use of the Ktrans parameter to evaluate and compare the
permeation of different NPs across a disrupted BBB rather than as a measure of the BBB
status. Use of a repeatable controlled cortical impact (CCI) mouse model serves to
minimize inter-animal injury variance, allowing for attribution of varying Ktrans to
differences between NP varieties. We utilize various CA-conjugated NPs to allow for
MRI monitoring of accumulation and retention in a mouse brain following TBI to assess
the robustness of the method to different NP types. We test the efficacy of Ktrans as a
method of measuring NP uptake kinetics at various time points following CCI. We also
show how this method compares to other more common means of measuring NP uptake
including the change in longitudinal relaxation rate (∆R1) and concentration maps.
Briefly, R1 (inverse of T1) describes the rate at which net magnetization realigns with the
magnetic field, B0, after application of the RF pulse, thus ∆R1 is the change in this rate
caused by the presence of a contrast agent or NP. This method holds promise for a range
of NPs to enable rapid evolution of their properties to promote desired accumulation and
retention kinetics in target tissue.

2.2 Materials and Methods
2.2.1 Ethics statement
All work with live animals in this study were performed in accordance with the
protocols approved by the Institutional Animal Care and Use Committee (IACUC) at the
University of Nebraska-Lincoln.
2.2.2 Materials
All chemicals were purchased from Sigma-Aldrich unless noted otherwise.
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2.2.3 MRI and image processing
All images were acquired using a 9.4 T (400 MHz for protons) 89 mm vertical
bore magnet (Varian, Walnut Creek, CA) with a 4 cm Millipede RF imaging probe with
triple axis gradients (100 G/cm max). Specific imaging sequences and parameters that
were used are provided in the relevant Methods sections. All acquired images were then
processed in MATLAB 2017 (MathWorks, Inc., Natick, MA) as described in the relevant
methods sections.
2.2.4 Controlled cortical impact mouse model for TBI
The CCI mouse model of TBI was chosen due to its high reproducibility and low
mortality rates among other models of TBI, as well as the common factors held between
human contusions and haemorrhaging from similar concussive wounds.100 Female
C57BL/6J mice were purchased from The Jackson Laboratory at an age of 6 weeks and
acclimated for 1 week prior to use. Anaesthesia was induced via inhalation of 4%
isoflurane gas then the mouse was secured in a stereotaxic frame (David Kopf
Instruments, Tujunga, CA) and maintained at 1.5% isoflurane for the duration of the
procedure. After induction of anaesthesia mice were injected subcutaneously with
Buprenorphine SR (0.1 mg kg-1). Hair was removed from the incision site on top of the
head using a depilatory agent (Nair), then the scalp was disinfected with a betadine scrub
followed by isopropanol wipes. Lidocaine (0.05 mL at 5 mg mL-1) was applied topically
to the scalp as an analgesic. A midline incision of roughly 1 cm was made over bregma
and a 2 mm cranial window was made over the left frontoparietal lobe (2 mm left and 2
mm posterior from bregma) using a surgical drill. A controlled cortical impactor
(Hatteras Instruments, Cary, NC) with a 2 mm tip attached to the stereotaxic frame was
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used to impact the brain normal to the dural surface at 4 m s-1 to a depth of 2.5 mm with a
dwell time of 80 ms to generate a moderate injury severity.101 Post-impact, the incision
was closed with surgical adhesive and the mouse was monitored until regaining
consciousness. Mice entered the imaging study at various time points (as reported in the
figures) between 1–48 hrs post-surgery. Surgery was performed on a total of 40 animals
in this study, though data were fully processed for only 36 animals. Two animals died
shortly after contrast injection, likely due to introduction of air bubbles from the tail-vein
catheter into the circulatory system of the mouse, and data acquisition was stopped. Data
from 2 other animals were excluded due to motion during data acquisition.
2.2.5 NP synthesis
PLGA NPs were composed of the following materials: poly(lactic-co-glycolic
acid) (PLGA) (5–25 mg) for the core, 1, 2-Distearoyl-sn-glycero-3phosphoethanolamine-Poly(ethylene glycol) (DSPE-PEG) (1 mg) to stabilize the surface,
DSPE-N-diethylenetriaminepentaacetic acid (DSPE-DTPA-(Gd)) (1 mg) for MRI
contrast, and DiD oil (25 μg) for fluorescence imaging. The NP materials were dissolved
in an acetone:methanol (85:15) organic phase, while 2% sodium cholate was dissolved in
ddH2O as the aqueous phase. A nanoprecipitation technique was used to form NPs,
wherein organic phase (1 mL) was added dropwise to the aqueous phase (10 mL) under
rapid stirring. Organic solvent was evaporated for one hour to harden the NPs.
The Cj-1 construct represents a Mn-porphyrin-polymer conjugate. Mn(III) mesoTri(N-ethylpyridinium-2-yl)-mono(N-carboxy-methyl)porphyrin was synthesized from
meso-tetra-(2-pyridyl)porphyrin via a four-step procedure. Preferential mono-alkylation
was achieved with tert-butylbromoacetate at feeding ratio close to 1:1 followed by
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quaternization reaction with an excess of ethyl iodide.102 Tert-butyl protecting groups
were then removed in alkali conditions (KOH/THF). Metallation was completed by
treating the resulting porphyrin with an aqueous MnCl2 solution at pH = 9.0 for 2 h and
the reaction product was purified according to a previously reported procedure.102 The
structure of the final product was confirmand by 1H-NMR and inductively coupled
plasma mass-spectroscopy (ICP-MS). Synthesized Mn-porphyrin was then conjugated to
poly(ethylene glycol)-poly(L-γ-benzyl-glutamic acid) block copolymer (PEG-P(Bzl)Glu)
via ethylene diamine linkers. Briefly, PEG-P(Bzl)Glu copolymer was synthesized as
described previously.103 The lengths of PEG and PEG-P(Bzl)Glu blocks were 114 and 40,
respectively, as determined by 1H-NMR. PEG-P(Bzl)Glu (1 eq) was reacted with 100 eq
of freshly distilled ethylenediamine in dry DMF at 45°C for 24 h. The product was
isolated by precipitation with cold diethyl ether and dried under vacuum. Mn-porphyrin
was conjugated to prepared block-copolymer via EDC/NHS chemistry and purified by
dialysis (MWCO 3,500) against water. Based on ICP-MS analysis, grafting degree was 8
porphyrin units per polymer chain. In aqueous solutions Mn-porphyrin-polymer
conjugates formed small micelles (about 80 nm in diameter) with uniform particle size
distribution (PDI = 0.24).
Pro-NP were prepared by ProTransit (Omaha, NE) using a water-oil-water
emulsion and solvent evaporation method.104 First, a 3% w/v poly(vinyl alcohol) (PVA)
solution was prepared by adding the desired amount of PVA into distilled water under
magnetic stirring. After stirring for 2 h at 600 rpm and 75 °C, the solution was allowed to
stir at RT overnight. The PVA solution was then vacuum filtered through a 0.22 µm
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polyethersulfone membrane. For nanoparticle preparation, 85 mg of the PLGA polymer
and 9 mg of (+)-dimethyl L-tartrate (DMT, used to stabilize the surface) was dissolved in
3 mL dichloromethane (DCM) and allowed to stir overnight. To this polymer solution
was then added DiD oil (8 µL, 50 mg mL-1), bovine serum albumin (BSA, 250 µL, 120
mg mL-1), and DSPE-DTPA-(Gd) (162 µL, 50 mg mL-1 in DCM). The preparation was
then emulsified using a staged microtip probe sonicator set at an energy output of 55 W
for 2 min, 40% amplitude over an ice-bath to form the initial water-in-oil emulsion. This
primary emulsion was added into 18 mL of the 3% w/v aqueous PVA solution and
sonicated for 3 min, 40% amplitude over an ice-bath to form an oil-in-water emulsion.
The resulting emulsion was stirred overnight at 600 rpm under a chemical hood to
evaporate DCM and to form Pro-NP. Afterwards, the Pro-NP suspension was kept in a
vacuum desiccator with magnetic stirring to ensure that all DCM had evaporated. The
formed Pro-NP was recovered by centrifugation at 24,000 rcf using a 50.2 Ti rotor, for 30
min at 4°C. Pro-NP were washed three times with distilled water to remove excess PVA.
The final pellet was resuspended in 18 mL distilled water, frozen at -80°C in a freezer,
and then lyophilized for 48 h to obtain dry powder.
2.2.6 Phantom tube preparation
A 0.25 mM (11.25 mg mL-1) solution of PLGA NPs was prepared and then
diluted with PBS to concentrations of 0.25, 0.125, 0.0625, 0.03125, .0156, and .0078
mM. Each concentration in the same volume of PBS (400 μL) were transferred into seven
separate 0.5 mL glass test tubes. The test tubes were arranged in order of decreasing
concentration and inserted into a custom-made holder to secure the tubes in the centre of
the magnet during imaging. Dilutions for Pro-NP,Cj-1 NPs, and Gd-DTPA were prepared
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in a similar manner with different maximum concentrations, of 0.65 mM (20 mg mL-1),
0.025 mM (0.5 mg mL-1), and 0.5 mM respectively. Pro-NP phantom tubes, for example,
had concentrations of 0.65, 0.325, 0.163, 0.0813, 0.0406, and 0.0203 mM with a tube of
pure PBS as a blank.
2.2.7 NP relaxivity characterization
NP relaxivity was calculated from MR images acquired using the 9.4 T MRI
system described above. After phantom preparation, the NPs were placed in the scanner
and cross-sections of the phantoms were imaged. A fast spin echo imaging sequence was
implemented using the following parameters: TE = 32.42 ms, 128×128×3 voxels,
25×25×3 mm3 FOV, and a seven TR values ranging from 200–2000ms in increments of
300 ms. The saturation recovery method was used to calculate the relaxation time T1 of
each voxel by fitting the MR signal to the following equation:
𝑆𝑆 = 𝑆𝑆0 �1 − 𝑒𝑒

−

𝑇𝑇𝑇𝑇
𝑇𝑇1

�

(14)

where S is the MR signal for a given voxel, S0 is the signal of that voxel at saturation, and
T1 is the longitudinal relaxation time of the given voxel. ROIs were drawn over each tube
and average T1-values calculated. Relaxivity was calculated for each NP by plotting
against NP concentration and finding the slope based on the following equation:
𝑅𝑅1 = 𝑟𝑟 ∗ 𝐶𝐶 + 𝑏𝑏

(15)

where R1 = T1-1, C is the NP concentration, 𝑏𝑏 is the intercept of the line, and r is the
relaxivity of the NP in units 𝑚𝑚𝑀𝑀−1 𝑠𝑠 −1.

2.2.8 Mouse preparation for imaging
Prior to imaging, mice were induced via inhalation of roughly 3% isoflurane gas
and maintained using roughly 1.5% isoflurane. Mice were secured in a cylindrical animal
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holder to fix the head and body position of the animal during imaging. A pressure-based
breathing monitor (SA Instruments, Stony Brook, NY) was secured over the back of the
animal and isoflurane levels were adjusted to maintain a breathing rate between 40 and
70 breaths per minute. A tail-vein catheter with a 27-G needle was inserted into the tail
and secured with surgical tape. The catheter tubing connected the needle to a 1 mL
syringe at the base of the animal holder, which remained outside the bore of the magnet
during imaging. Mice were injected with 100 µL PBS containing either 0.2 mM (9 mg
mL-1) PLGA NP in PBS (100 μL), 0.1 mM (2 mg mL-1) Cj-1, 0.65 mM (20 mg mL-1)
Pro-NP, or 0.5 mM Gd-DTPA via the catheter followed by a 100 µL bolus of PBS ensure
all CA was expelled from the catheter and into the animal. Individual mice were injected
with a single dose of one NP type, the number of individuals in each NP group were: Cj-1
n = 2, PLGA n = 17, Pro-NP n = 10, and Gd-DTPA n = 7. Group sizes for Cj-1 and ProNP were selected based on NP availability. PLGA and Gd-DTPA group sizes were
selected to investigate the effect of post-injury injection time on uptake both within and
between groups.
2.2.9 MRI data collection
Animal imaging was performed using the 9.4 T MRI system described above.
Animals were imaged using a variable flip angle gradient echo sequence with two flip
angles for rapid calculation of R1.69 Animal imaging was performed on the same imaging
system utilized for relaxivity characterization. The parameters for the gradient echo
sequence were as follows: TR = 54.24 ms, TE = 2.73 ms, 128×128 data matrix, 10 slices
each with a FOV of 20×20×1 mm3, and 5 averages for a scan time (temporal resolution)
of 34s. Two baseline scans were acquired prior to injection of the NPs using flip angles
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of 10° and 30° respectively. All post-injection scans used a flip angle of 30°. At the
conclusion of pre-injection scans, NPs were injected through the tail-vein catheter
immediately followed by acquisition of roughly 100 scans over the course of 1 h postinjection.
2.2.10 Concentration mapping
Images were processed using in-house software in Matlab 2017. R1 was calculated
using the variable flip angle equation in slope-intercept form (eq 3). By plotting the ratio
of S to sin(α) versus the ratio of S to tan(α) for multiple values of α a curve is generated
whose slope is equal to E1, from which R1 can be calculated. Concentration of the NP at a
given time point was then calculated using equation (5). NP concentration was calculated
at every voxel to create concentration maps for each animal at every time point.
2.2.11 Ktrans mapping
Pharmacokinetic parameter Ktrans was extracted from the concentration maps
using the reference region equation, which is derived from the extended Tofts’ model:57
𝐶𝐶𝑇𝑇𝑇𝑇𝑇𝑇 (𝑇𝑇) =

𝐾𝐾𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡,𝑇𝑇𝑇𝑇𝑇𝑇
𝐾𝐾𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡,𝑅𝑅𝑅𝑅

∗ 𝐶𝐶𝑅𝑅𝑅𝑅 (𝑇𝑇) +

𝐾𝐾𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡,𝑇𝑇𝑇𝑇𝑇𝑇
𝐾𝐾𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡,𝑅𝑅𝑅𝑅
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(16)

where CTOI(T) and CRR(T) are the concentration of NP at a given time in the tissue of
interest (TOI) and reference region (RR), respectively. Muscle tissue was used as the
reference region in all animals, which is shown by the blue ROI in the structural image of
Figure 2.3. A least squares curve fitting routine was employed using Matlab to extract
Ktrans for each voxel in the brain. Mean Ktrans values from focal and contralateral ROI’s,
shown as red and green ROIs respectively in Figure 2.3, were recorded for each mouse,
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separated by NP type, and reported in Figure 2.6. Mean Ktrans values for PLGA NPs and
Gd-DTPA were further grouped by post-injury injection time and are reported in Figure
2.7.
2.2.12 Additional pharmacokinetic characterization
NP pharmacokinetic parameters (Table 2) were calculated based on AIFs
collected from ROIs drawn in carotid artery in posterior-most slices of MR images. ROIs
were selected in either carotid artery based on noise and level of signal enhancement, so
that AIF reflected expected maximum concentration values. AIFs were based on average
concentration versus time curves from multiple slices of the same individual where
possible. Averaged AIFs were fit to a biexponential using a nonlinear least squares
algorithm in Matlab:105
𝐶𝐶𝑝𝑝 (𝑡𝑡) = 𝐴𝐴𝑒𝑒 −𝛼𝛼𝛼𝛼 + 𝐵𝐵𝑒𝑒 −𝛽𝛽𝛽𝛽

(17)

where Cp is the plasma concentration, A and α are the linear component and rate constant
respectively corresponding to the distribution phase, and B and β are the linear
component and rate constant respectively corresponding to the elimination phase. t1/2,dist
was calculated as the time between a point, A1, on a line with slope A and another point,
A2, such that A1 is 2*A2. t1/2,elim was calculated in the same manner instead using a line
with slope B. Elimination constants, Kel, were calculated as:
𝐾𝐾𝑒𝑒𝑒𝑒,𝑖𝑖 = ln(2) /𝑡𝑡1/2,𝑖𝑖

where i indicates the phase, distribution or elimination.
2.2.13 Statistical Analysis
All statistical analyses were performed using GraphPad Prism 7.0e. Average
concentration and Ktrans values were compared between NP types or injection times

(18)
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using one-way ANOVA followed by Tukey’s post-test to determine statistical difference
between specific groups. Statistical significance was defined as p < 0.05.

2.3 Results
2.3.1 NP Characterization
Dynamic contrast-enhanced MRI (DCE-MRI) can be used to measure NP
accumulation in a tissue of interest (e.g., damaged brain tissue) and various physiological
parameters of that tissue based on the kinetic model used to most accurately represent
that tissue.106 T1-signal can be directly used to detect accumulation in the brain, but a
series of T1-weighted images can be further analysed to more fully quantify tissue
properties once NP relaxivity has been quantified using MRI.37 Quantification of R1
relaxivity (Table 1) shows the relaxivity of PLGA NPs as 4.78 (s-1mM-1) with respect to
Gd concentration in NPs compared with 4.1 (s-1mM-1) for Gd-DTPA, though the R2/R1
value for PLGA NPs was higher than that of Gd-DTPA, 5.32 compared with 1.12. While
they show similar R1 relaxivities, the differing R2/R1 values indicate they are not highly
similar in their function as CAs. In contrast to the PLGA NPs, the Pro-NPTM and Cj-1
NPs showed lower R1 relaxivities of 2.63 and 2.60 (s-1mM-1 CA) respectively, and much
higher R2/R1 values of 42 and 12.3 respectively. These differences in relaxivities between
the CAs allowed us to test how our imaging procedures are affected by different contrast
enhancing properties. NP hydrodynamic sizes were also varied with Cj-1 NPs being the
smallest at 80 nm, PLGA NPs having a similar size of 89 nm, and Pro-NP NPs having a
size of 214 nm as determined by DLS. Gd-DTPA acts as a nice surrogate for a small
molecule drug with a size of approximately 0.83 nm.107

32
Table 2.1 NP properties
Particle

Size
(nm)

Contrast Agent
concentration
[mmol CA mg-1
NP-1]

Polydispersity
Index (PDI)

R1
Relaxivity
[s-1 mM-1]
at 9.4 T

R2/R1

Zeta
Potential
[mV]

Injection
Dose

Cj-1

80

5.1×10-5

0.24

2.60

12.3

+13.1

0.9 mg
mouse-1

PLGA

89

2.29×10-5

0.41

4.78

5.32

-28.8

0.2 mg
mouse-1

Pro-NP

214

1.635×10-6

0.036

2.63

42.0

-10.3

2 mg
mouse-1

GdDTPA

0.83

1.07 mmol Gd
mg-1 Gd-DTPA-1

N/A

4.1

1.12

N/A

0.05
µmoles
mouse-1

2.3.2 Pharmacokinetics
Assessment of the pharmacokinetic parameters, which describe the behavior of
NP in the blood, is a common preliminary method to gather some predictive information
on the functionality of an agent.108 MRI data from the imaging sequence included several
slices containing the carotid arteries, allowing for blood concentration measurements
from the injection of NP to the end of the imaging period. Pharmacokinetic
quantification of NPs105,109 (Table 2) showed slower elimination of all NP types in
comparison to Gd-DTPA. PLGA NPs showed longest elimination half-life (t1/2,elim) at 44
minutes, Cj-1 and Pro-NP were similar with respective t1/2,elim of 29.7 and 27.7 minutes.
As expected, Gd-DTPA showed the shortest t1/2,elim of 15.7 minutes. On the contrary all
distribution phase half-lives (t1/2,dist) were similar, varying between about 3 and 5 minutes
among the different contrast agents. Mean area under concentration-time curve (AUC)
values were calculated for the 60-minute imaging session for each particle type.
Comparison of AUCs showed a large variation amongst NP types, there existed a roughly
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40-fold difference between means of Cj-1 and Pro-NP. Note the difference in AUC units
between Gd-DTPA and the three NPs.
Table 2.2 NP pharmacokinetic properties
Kel,dist [min-1] Elimination
Kel,elim [min-1]
Half-life
(t1/2,elim)110

Particle

Distribution
Half-life
(t1/2,dist)110

Cj-1

4.74±1.58

0.16±0.055

29.69±2.53

0.024±0.002

PLGA

3.12±1.33

0.25±0.068

44.02±14.23

0.017±0.005

Pro-NP

3.64±1.79

0.23±0.11

27.74±10.19

0.029±0.012

Gd-DTPA

4.01±2.47

0.23±0.11

15.70±8.50

0.056±0.023

Area under
concentrationtime curve
(AUC)
152±59 [min
mg mL-1]
329±130 [min
mg mL-1]
6116±3200
[min mg mL-1]
6.6±3.8 [min
mM]

2.3.3 ∆R1 and Concentration maps
To evaluate BBB permeability based on NP properties following TBI, one of four
NP types was injected in a CCI mouse model at a specific time point after injury. While
an individual mouse was injected with only one NP type at one time point, different postinjury injection times and particle types were assigned to other individuals. T1-weighted
MR images were collected over a 1-h period following NP injection, enabling
visualization and quantification of change in R1 over time based on NP uptake. Variation
between NP types in their contrast enhancement in a TBI can be seen in ∆R1 maps
(Figure 2.1), which compare R1 maps corresponding to specific time points with the preinjection R1 map, but in all cases NPs and Gd-DTPA were observed in the damaged brain
tissue further supporting the idea of an EPR-like effect in TBI. By dividing ∆R1 maps by
the relaxivity values of the NPs, NP concentration maps were generated to provide a
snapshot quantification of the amount of NP present in the TBI.
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Figure 2.1 Structural MRI, ∆R1, and concentration maps for the three NPs and Gd-DTPA. Structural
images show injury, dark area near top of brain, ∆R1 and concentration maps show change in R1 and NP
concentration between final and initial scans. Highest ∆R1 and concentration values correspond to the
injured regions in the structural images. Concentration units for Gd-DTPA have been displayed as mM and
for NPs as mg/mL in an attempt to maintain use of units most familiar for these particles.
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NP accumulation was compared in the focal region of the injury, the contralateral
region on the non-injured side of the brain, and a muscular reference region. ROIs were
drawn in these brain regions (Figure 2.3) to quantify NP uptake by location. NP
concentrations in the brain were greater in the focal injury than the contralateral
hemisphere across all particle types (Figure 2.1), further supporting an EPR-like effect in
TBI. These time-course measurements were then used to model (black lines in Figure
2.4) NP uptake and accumulation kinetics in various brain regions to determine Ktrans.

Figure 2.2 (A) Average final concentration values between NP types. No significant difference was
detected between NPs despite differences in size and relaxivities. (B) Average final concentration values of
PLGA NPs by post-injury injection time. * indicates a significant difference (p < 0.01) determined using
one-way ANOVA followed by Tukey’s post-test. Inlays show scaled concentration values in contralateral
brain by NP type and injection time.
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Final concentration values in the focal region were significantly higher (p < 0.01)
than those in the contralateral hemisphere in PLGA NPs and Pro-NPs (Figure 2.2A).
Comparison of focal and contralateral final concentrations in Gd-DTPA showed a nonsignificant difference in means. No significant differences were seen between particles
within the same brain region. When comparing PLGA NPs between injection times,
significantly higher (p < 0.005) final concentration in the focal injury is seen following
injection at 3 h post-injury compared to 2, 4, and 48 h time points (Figure 2.2B). No
difference was detected between injection times in the contralateral hemisphere.
2.3.4 Ktrans mapping
Ktrans maps (Figure 2.5) were generated using the integral form of the Kety
equation and a highly vascularized muscular reference region to compare with the signal
intensity changes in the tissue of interest.106 Comparison of Ktrans across NPs (Figure 2.6)
showed no significant difference between NPs within the same brain regions when
averaged across all injection times. Significantly higher (p < 0.01) uptake was detected in
the focal injury compared with the contralateral hemisphere for PLGA NPs and Pro-NP
as well as the small molecule agent Gd-DTPA.

Figure 2.3 Region of interest model (left) used for calculating and analyzing average NP pharmacokinetics.
Red corresponds to the focal injury, green to the contralateral region, and blue to the muscular reference
region. Concentration maps (right) showing change in NP concentration over imaging session.
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Figure 2.4 R1 values in TBI focal region, reference region, and contralateral over time calculated from
DCE-MRI with A) Cj-1 NPs B) PLGA NPs C) Pro-NP D) Gd-DTPA. Sample regions are shown in
corresponding colors in Figure 2.3. Black lines show fitted curves for each region with each of the data
points showing the experimental data.

PLGA NPs were found to still accumulate in damaged brain when injected up to
48 hrs post-CCI though peak accumulation achieved when injected 3 h post-CCI. Focal
Ktrans values 3 h post-injury (mean of 0.170 min-1) were significantly higher than Ktrans
values for the same region at 2 (p < 0.01), 4 (p < 0.05), and 48 h (p < 0.01). This
corresponds to a 125-fold increase in accumulation and retention kinetics over
contralateral brain at the same 3 h post-injury time point (mean of 0.00135 min-1).
Despite lower focal Ktrans values, NP accumulation in focal injury when injected 48 h
post-injury was still approximately 11-fold higher than contralateral brain.
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Comparison of Ktrans values for PLGA NPs and Gd-DTPA grouped by post-injury
injection time (Figure 2.7) showed significantly higher (p < 0.05) accumulation and
retention kinetics of PLGA than Gd-DTPA in the focal injury when administered 3 h
post-injury. Despite showing much lower accumulation and retention kinetics in the focal
injury than PLGA NPs when injected 3 h post-injury, Gd-DTPA Ktrans in focal injury still
showed an approximately 25-fold increase over contralateral brain indicating delivery to
injured tissue. Gd-DTPA showed no significant difference in Ktrans based on injection
time. Ktrans in focal injury (mean of 0.082 min-1) showed 62-fold increase over
contralateral brain (mean of 0.0013 min-1) with Pro-NP. Cj-1 showed the a 144-fold
increase in Ktrans in the focal injury (mean of 0.1440 min-1) compared with contralateral
brain (mean of 0.0010 min-1) though this difference was not statistically significant.

Figure 2.5 Ktrans maps and corresponding structural MR images for all NP types. Structural images
provide information on the injury location in the brain. Maximum values in Ktrans maps (dark red)
correspond to injury shown in the structural images (darker brain regions). This correspondence indicates
areas of highest uptake are damaged tissue.
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2.4 Discussion

The lack of effective therapies for TBI represents a critical need for the

development of new delivery strategies for improved target engagement. NPs are
uniquely suited for delivery into the brain following a TBI because of an EPR-like effect
caused by BBB breakdown.54 However, there is still little information available on which
NP properties ideally promote rapid accumulation and extended retention within the
injury. Therefore, the goal of this work was to develop a robust method for assessing
accumulation and retention of various types of NPs within a TBI using MRI that could be
used to rapidly evolve desirable NP properties.In this study we used three different NPs
(negatively charged 89 nm PLGA NPs, negatively charged 214 nm Pro-NPs, positively
charged 80 nm Cj-1 NPs) and the small molecule CA, Gd-DTPA. These different NPs
were chosen because of their wide range of hydrodynamic sizes as well as different zeta
potentials, which allows us to test the robustness of our imaging method to NP
parameters. We first compared the relaxivities of the NPs to assess their ability to provide
contrast in MRI. The similar relaxivity but differing R2/R1 values for PLGA NPs and GdDTPA indicate a similarity in their function as CAs, though not to a high degree. Pro-NPs
and Cj-1 showed similarity to one another in terms of relaxivity but were lower than the
PLGA NPs and Gd-DTPA. Despite the relaxivity differences, the imaging and processing
protocols were shown viable with all NP types. Despite the differences in R1 relaxivities
between particle types, ∆R1 maps highlighted the injured region with higher values across
all particles (Figure 2.1). Quantification of different ROIs in concentration maps showed
higher focal concentration with PLGA NPs administered 3 h post-injury compared with
other administration times, similar to observations from Bharadwaj et al., using
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fluorescent NPs.53 However, no differences were seen across administration times in GdDTPA, indicating a possible interaction effect on uptake between particle properties and
post-injury administration time. This emphasizes the need for further analysis to optimize
time of injection for unique particle types where a robust imaging method will allow for
rapid optimizations.
The different NPs showed slight differences in pharmacokinetics following
injection into TBI mice. The longer t1/2,elim of the NPs likely corresponds to decreased
renal clearance commonly observed for particles over ~8 nm in diameter as comapred to
a small molecule like Gd-DTPA, which is cleared through the kidneys.93,94 The increased
plasma retention times of NPs may lead to increased uptake by elongating the time period
during which transfer from plasma into the brain injury can occur. The unique
pharmacokinetic parameters of Gd-DTPA are likely the cause differences seen in its
uptake curves (Figure 2.4). Gd-DTPA uptake differs from the three NPs in that highest
uptake is seen in the focal region, whereas NPs show higher uptake in the reference
region. Gd-DTPA more readily moves into the extracellular space throughout the body
while the NPs remain within the vasculature for a longer period. As the NP concentration
remains higher in the blood pool, they provide further enhancement in the highly
vascularized reference region. AUC values differed greatly between particles, though it
must be noted that the units used for NPs are different than those for Gd-DTPA as
concentrations of these agents are not typically expressed in the same units. AUC
variation is also attributable to the differences between injection concentrations of NPs
(Table 2.1). PLGA NP concentration was selected to match the Gd concentration of Gd-
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DTPA dose, ProNP concentration was selected based on previous antioxidant studies
using the particle, and Cj-1 concentration was selected in effort to provide similar
contrast enhancement to Gd-DTPA and PLGA NP. As particles differ in their contrastenhancing properties, the concentrations required for enhancement also differ, making
comparison of AUCs between particle types difficult.
There was no significant difference in contralateral concentrations between
administration times in PLGA NPs or Gd-DTPA. This lack of difference was likely a
result of BBB integrity being maintained at early time points following brain impact in
the undamaged tissue. While the generation of ∆R1 and concentration maps at multiple
time points for each individual provides valuable data, a full understanding of uptake and
retention must incorporate kinetic information. The information a concentration map
provides at some time t does little to describe what occurred before that point or what will
occur after. It is also difficult to distinguish what CA is still in the blood pool and will be
rapidly removed or what has permeated into the tissue pool and will be retained. To better
quantify NP permeability across the disrupted BBB, we must account for both
accumulation and retention of NPs in the damaged tissue. Ktrans incorporates plasma and
tissue concentrations over the entire collection period to calculate a single value for each
voxel. By comparing the relation of plasma and tissue concentration over time, Ktrans
provides permeation information unavailable in a single concentration map.
Determination of Ktrans often relies on knowledge of the arterial input function
(AIF), which describes NP concentration in blood plasma (Cp) at time t after injection.106
Estimating the AIF is typically done in one of three manners: (1) Blood sampling via
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arterial catheter concurrent with the imaging procedure allows for assessment of Cp via
spectroscopic methods, but the small total blood volume of mice limits the number of
samples that can be collected creating poor temporal resolution of the AIF. (2) A general
AIF model can be created by measuring and averaging Cp over time from a number of
sample individuals and then used to analyse the DCE-MRI images from individuals
outside the sample cohort.111 This model neglects the possible variation that may exist
between sample groups and individuals within those groups and does not account for
variabilities in injection volumes through the tail vein. (3) The third method is to estimate
the AIF from the images in the data set by converting the blood signal intensity to Cp.
This method is contingent upon the presence of a large blood vessel in the field of view
and is susceptible to inaccuracies caused by partial volume effects. The method is also
hindered by the need for both high temporal and spatial resolution to accurately estimate
AIF, as increasing temporal resolution negatively affects signal-to-noise ratio (SNR) and
spatial resolution.106 Ktrans maps can be estimated without the AIF, using the integral form
of the Kety equation and a highly vascularized muscular reference region to compare
with the signal intensity changes in the tissue of interest.106,112 By calculating the ratio of
the tissue of interest Ktrans to the reference region Ktrans we can measure the relative
difference in permeability between healthy brain tissue and damaged tissue without the
need for an AIF. Therefore, for these studies we used the Kety equation and a muscular
reference region106,112 to determine Ktrans and generate Ktrans maps.
Ktrans mapping showed significantly higher uptake kinetics in the focal injury than
in contralateral brain with PLGA NPs and Pro-NPs (p < 0.01). A significant difference (p
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< 0.05) between contralateral and focal regions was shown in Gd-DTPA using Ktrans but
was not seen when comparing final concentration values, showing the higher sensitivity
of the Ktrans method. Indeed, comparison of final concentration values in focal and
contralateral regions in Cj-1, PLGA, Pro-NP, and Gd-DTPA showed fold differences of
10.7, 5.5, 7.3, and 5.8 respectively. Ktrans comparison between focal and contralateral
regions showed far greater fold differences of 145, 125, 62, and 25 respectively, showing
increased sensitivity of Ktrans for detecting CA accumulation and retention.

Figure 2.6 Average Ktrans values between NP types. No significant difference was detected between NPs
despite differences in size and relaxivity. PLGA NPs, Pro-NP and Gd-DTPA show a significant increase (p
< 0.01) in Ktrans in the focal injury as compared to contralateral brain. Inlay shows a scaled comparison
between NPs on the contralateral side of the brain. Inlay shows scaled Ktrans values in contralateral brain
by NP type.

Comparison of Ktrans between focal injury and contralateral brain showed higher
fold differences in the three NPs than in Gd-DTPA, providing further support of an EPRlike effect in TBI; NPs show a greater uptake and retention as shown by higher Ktrans in
damaged tissue compared with healthy tissue than the small molecule Gd-DTPA whereas
differences in concentration were not as dramatic. This also suggests the occurrence of
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passive targeting, supporting the use of NPs in TBI. Uptake is limited in healthy tissue
and increased in the damaged tissue where a therapeutic effect is desired.

Figure 2.7 Average Ktrans values for (A) PLGA NPs and (B) Gd-DTPA in the focal injury and
contralateral brain when injected I.V. at various times after injury. NPs showed a time-dependent difference
in uptake and retention kinetics as compared to Gd-DTPA where uptake and retention were not
significantly affected by injection time. * indicates a statistical difference (p < 0.01). Inlays show scaled
Ktrans values for each injection time on the contralateral side of the brain.

Contralateral Ktrans values at 48 h were curiously higher than those observed at
other time points for mice injected with PLGA NPs, though the difference was not
statistically significant. This increase was not observed in the concentration mapping
carried out at the 1 hr time point (Figure 2.2B), supporting the increased sensitivity of
Ktrans in situations of minor BBB disruption. This increase in Ktrans may correspond to a
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spread of minor BBB breakdown from the focal region to other parts of the brain that was
not detectible with standard concentration mapping imaging techniques and merits further
investigation. The focal and contralateral uptake at 48 h post-injury may also indicate a
wider treatment window than previously described, meaning NP treatments could still be
effective even when administered at extended time points after injury.113
A potential limitation of this study is the possibility of B1 artefact creating error within T1
measurements, ultimately affecting Ktrans maps. As uptake quantification from the
dynamic image series is based on differences from the pre-contrast T1 scan, accurate T1
measurement is essential. Transmit radio frequency (B1) field inhomogeneities can
negatively affect the accuracy of T1 measurements and typically increase in severity with
field strength.114 To compensate for B1 inconsistencies, intensity-based postprocessing
methods can be applied,115 though compensation can also be carried out through B1
mapping prior to dynamic sequence collection. A common B1 compensation method is
the double-angle method, which serves to determine the true flip angle at each voxel by
comparing two images with flip angles α and 2α acquired with a long TR to minimize T1
effect.116
Pre-contrast B1 mapping was not performed in this study, though large B1 artefact
was not apparent in collected images at different time points in imaging series. Intensitybased postprocessing B1 correction115 was performed on a subset of images for
comparison with uncorrected originals. Normalized original MR images and
concentration maps were compared with their B1 corrected equivalents though
differences were minor, mean focal concentration values in original and corrected maps
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showed no significant difference (p > 0.05) when comparing a randomly selected sample
of 8 mice with a paired t-test. The lack of strong B1 artefact may be related to the narrow
field of view (FOV), 20×20×1 mm3, utilized for imaging. The inhomogeneities present
over a field of this size may be less impactful than those present in an FOV for human
imaging, which can be larger in area by a factor of 100 or more depending on the tissue
being investigated.

2.5 Conclusion

Our results show the efficacy of Ktrans as a robust method for measuring NP

uptake and retention kinetics in TBI across various NP types and relaxivity properties.
This method will allow researchers to rapidly evolve NP characteristics to improve
delivery. Using Ktrans as a measure of NP ability to accumulate and be retained in target
tissue allowed us to determine that PLGA NPs had the highest accumulation and
retention kinetics when injected 3 hours post-injury, though uptake was still detected
when NPs were injected 48 hours post-injury. Additionally, we showed the methods
described in this paper are viable for a variety of NPs with varying relaxivity properties,
allowing for future uptake characterization of other CA-conjugated NPs. The adaptability
of this method highlights the utility of image-guided NPs for assessing accumulation and
retention kinetics to correlate with therapeutic efficacy. This will allow for a more rapid
advancement of lead NP-based therapeutics and hopefully help overcome the current
therapeutic stalemate for TBI.
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CHAPTER 3: DIFFERENTIAL NANOPARTICLE
ACCUMULATION KINETICS IN VULNERABLE AND STABLE
ATHEROSCLEROTIC PLAQUES
3.1 Introduction

Atherosclerosis is a chronic cardiovascular condition characterized by the

development of inflammatory lesions within the arterial wall accompanied by lipid
deposition and immune cell recruitment.117 The plaques formed at these sites can exhibit
either stable or vulnerable phenotypes, the latter being characterized by a thin fibrous
cap, large necrotic lipid core, neovascularization, and immune cell infiltration.118 Plaque
rupture, most common within vulnerable plaques, accounts for 60-75% of coronary
thrombi, leading to myocardial infarction or ischemic stroke.118,119 Current treatments for
atherosclerosis focus on lowering low-density lipoprotein (LDL) within the blood
through the use of statins.120 Immunomodulatory agents show promise for reduction of
inflammation in atherosclerosis, though side effects complicate the safe and effective
implementation of immunosuppressants. To help minimize off-target effects nanoparticle
(NP) drug delivery systems can be customized to optimize properties including size,
targeting ligands, and surface coating for delivery to the desired tissue.90 Dysfunction in
endothelial cells within plaque regions results in widening of junctions between adjacent
cells, enabling paracellular transport from blood into the plaque across the luminal vessel
wall.121 Previous work has shown NP accumulation within atherosclerotic plaques using
magnetic resonance imaging (MRI) and fluorescence microscopy, though uptake
comparison between plaque morphologies has not been thoroughly investigated.55,121 As
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the role plaque morphology plays in NP accumulation kinetics is not well understood,
NP-based therapeutics are likely not optimized for maximal delivery. Additionally,
investigating the uptake kinetics of NPs from blood into plaques with DCE-MRI may
provide unique non-invasive diagnostic information about plaque morphology.
Despite the complicated pathobiology that eventually results in formation of
plaque of a particular morphology, first lesions tend to consistently form at locations of
disrupted blood flow, near arterial branch points for example.122 Introduction of abnormal
hemodynamics, low laminar shear stress (LLSS), high laminar shear stress (HLSS), and
oscillatory shear stress (OSS) in vitro alters endothelial morphology and oxidative
stress.123 In vivo models have shown plaque development following hemodynamic
modulation in the common carotid artery in regions that are atheroprotected under normal
hemodynamic conditions.124,125 Recent work has shown that not just plaque formation,
but also plaque morphology is influenced by local hemodynamics. Plaque induction in
ApoE-/- mice with a tapered cuff around one carotid artery to alter hemodynamics have
shown differing plaque morphologies dependent upon hemodynamic profile, with LLSS
resulting in vulnerable plaques, HLSS exhibiting atheroprotection, and OSS inducing
stable plaques.126,127 This model allows for direct comparison of NP behavior between
plaque morphologies in a single mouse model.
In this work MRI was utilized to monitor plaque development over 9 weeks
following implantation of a blood flow modifying carotid artery cuff in an ApoE-/- mouse
model of atherosclerosis. At 5 and 9-week timepoints DCE-MRI was performed to
measure uptake kinetics of contrast-enhancing NPs in both vulnerable and stable plaque
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morphologies. Histological imaging was performed after the 9-week DCE-MRI
experiment to quantify characteristics of both plaque morphologies.

3.2 Materials and Methods
3.2.1 FA-Gd NP Materials and Chemicals.
Gadolinium chloride hydrate (GdCl3·xH2O, 99.9%), triethylene glycol (TEG,
99%), sodium hydroxide (NaOH, ≥97%), folic acid (C19H19N7O6, ≥97%), ethyl-3-(3dimethylaminopropyl)-carbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS,
98%), were purchased from Sigma-Aldrich. Alexa Fluor 647 Cadaverine (AF647),
Dialysis kit FLOAT-A-LYZER G2 red (molecular weight cutoff, MWCO, 20 kDa) were
purchased from Thermo Fisher Scientific. Deionized water in the experiments was
obtained by using a Millipore water purification system.
3.2.2 Synthesis of FA-Gd NPs.
2 mmol GdCl3.xH2O was added into 30 mL of triethylene glycol in a 100 mL threenecked flask. The mixture was heated to 80 °C and magnetically stirred until the precursors
were completely dissolved into the solvent. Then, 6 mmol NaOH was added and continued
stirring for 4h at 180°C. To coat the hydrophobic magnetic NPs, 4 mmol folic acid was
added and the reaction continued with stirring for 12 h at 150°C. After completely cooling,
the synthesized nanoparticles were washed 3 times using deionized water.
3.2.3 Conjugation of AF647 to FA-Gd NPs.
AF647 was conjugated to NPs using EDC-NHS coupling. Briefly, 0.1mg/mL NPs
were taken into 40 mL amber vial. Then 0.37 mg/mL EDC and 0.12 mg/mL NHS were
added stepwise and the reaction continued with magnetic stirring. After that, 0.1 mg/ml
AF647 was added and stirring continued for 2 hours. Float-a-lyzer dialysis kit was then
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used to remove unconjugated peptide. The whole conjugation process was conducted in
the dark.
3.2.4 NP relaxivity characterization
R1 relaxivity of NPs was measured using a 9.4T (400 MHz) 89 mm vertical bore
magnet (Varian, Walnut Creek, CA) with a 4 cm Millipede RF imaging probe and triple
axis gradients (100 G/cm max). A fast spin echo sequence was used with the following
parameters: 7 repetition time, TR, values from 200-2000 ms in 300 ms increments, TE =
32.42 ms, ETL = 16, 25x25x3 mm3 field of view (FOV), and a 128x128 data matrix. The
saturation recovery method was utilized to measure relaxation time, T1, of each NP
concentration based on MR signal and the following equation:
𝑆𝑆 = 𝑆𝑆0 �1 − 𝑒𝑒

−

𝑇𝑇𝑇𝑇
𝑇𝑇1

�

(14)

in which S is MR signal at a given voxel and S0 is the signal of the given voxel at
saturation. Relaxivity, r in mM-1s-1, was the calculated as:
𝑅𝑅1 = 𝑟𝑟 ∗ 𝐶𝐶 + 𝑏𝑏

(20)

where R1 = T1-1, C is the concentration of NP and b is the y-intercept of the line.
3.2.5 Animal imaging
Mice were induced with roughly 2% isoflurane gas and maintained between 1%
and 2% to maintain breathing rates, measured with a pressure-based sensor (SA
Instruments), between 50 and 80 breaths per minute over the course of the imaging
sequence. Mice were affixed in a cylindrical animal holder to maintain head and body
position during imaging. A 30-G needle was connected to a syringe via catheter and
inserted into one of the lateral tail veins then secured with surgical tape. Mice were
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injection with 100 µL 0.5 mM FA-Gd NP solution followed by a 100 µL bolus of PBS to
flush all NP from the catheter.
3.2.6 DCE-MRI data collection
DCE-MRI was performed using a 2-D gradient echo sequence with two flip
angles for calculation of R1128 and generation of Ktrans maps based on a two-compartment
pharmacokinetic model as described previously.57 Briefly, two baseline scans were
performed to calculate T1 values prior to injection with the following parameters: TR =
138 ms, TE = 3.48 ms, flip angles of 10° and 30° respectively, 2 averages, 256x256 data
matrix, 20 slices each with a 23x23x0.5 mm3 FOV for a total scan time of 53 s. Postcontrast scans all used a flip angle of 30° with the same parameters as above. NPs were
injected after completion of baseline scans followed by 1 h of post-contrast image
collection. Ktrans maps were generated using a custom script written in MATLAB.

3.3 Results
3.3.1 Nanoparticle development.
Contrast-enhancing, folic acid-coated Gd NPs (FA-Gd) were synthesized and
characterized for use in DCE-MRI experiments. FA-Gd was conjugated with AF647 via
EDC-NHS for fluorescence imaging of arteries ex vivo following MR experiments. Highresolution transmission electron microscopy (HRTEM) was utilized to measure core size
and showed an average FA-Gd diameter of 4.5 nm (Figure 3.1A). FT-IR was performed
on free FA as well as FA-Gd (Figure 3.1B) to confirm the presence of FA on the surface
of Gd NPs. Shifting of the COOH peak from the free FA spectrum indicates coating of
FA on the Gd NP surface. Prior to DCE-MRI, the contrast-enhancing properties of FAGd were also quantified. Relaxivity characterization of FA-Gd used a saturation recovery
method of T1 measurement at 9.4 T and determined R1 relaxivity of 3.15 s-1mM-1 (Figure
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3.1C). Zeta potential assessment of FA-Gd (Figure 3.1D) showed a mean value of -40.5
mV.
Particle
FA-Gd

Table 3.1 Pharmacokinetics of FA-Gd in ApoE-/- mice determined by MRI.
Distribution
Kel,dist [min-1]
Elimination
Kel,elim [min-1]
Half-life
Half-life
(t1/2,dist)110
(t1/2,elim)110
17.36±10.26
0.067±0.068
46.82±14.50
0.016±0.0052

Figure 3.1 (A) HRTEM images of FA-Gd NPs, white circles indicate average diameter (4.5 nm) of the
NPs. Blue arrow indicates lattice fringe of NPs. (B) FT-IR spectra of folic acid and FA-Gd NPs. The black
spectrum corresponds to free folic acid, while the red spectrum corresponds to FA-Gd NPs. The COOH
peak was shifted from 1680 to 1527 cm-1, which confirmed the FA coating on to the Gd NPs. (C) R1 map
of FA-Gd NP phantoms for determination of R1 relaxivity (3.14 mM-1s-1). (D) Zeta potential distribution
of FA-Gd NPs, mean value of -40.5 mV.

53
3.3.2 Evaluation of nanoparticle accumulation and retention kinetics during plaque
evolution.
DCE-MRI using FA-Gd at the week 5 timepoint (Figure 3.2) showed no
significant difference between cuffed and normal arteries in the upstream or downstream
regions at week 5. At the week 9 timepoint however, significantly higher (p < 0.01) Ktrans
was recorded in the cuffed artery than the normal artery in the OSS region. The LLSS
region also showed a significant difference (p < 0.05) in Ktrans between cuffed and normal
arteries. The higher Ktrans values observed in the cuffed arteries indicate higher NP
accumulation in comparison to the normal arteries.

Figure 3.2 Comparison of Ktrans in ApoE-/- mouse model of atherosclerosis. Mean Ktrans was quantified
in the area surrounding the carotid artery lumen to minimize signal from blood while retaining signal from
plaque and endothelium in both the cuffed and control arteries. The highest Ktrans value from a single slice
within the cuffed artery was selected and compared with Ktrans in the control artery of the same slice. Data
are presented from DCE-MRI experiments at both 5 and 9 weeks and separated by hemodynamic profile.
Significantly higher Ktrans was measured in both LLSS and OSS plaques at week 9. (* p < 0.05, ** p <
0.01)
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Figure 3.3 Diagram of 1.5-mm cuff placement on left carotid artery of ApoE-/- mouse between the aortic
arch and bifurcation. Cuff creates three distinct hemodynamic profiles, one region of LLSS, which induces
formation of a vulnerable plaque, one of HLSS, which is atheroprotective, and one of OSS, which induces
formation of a stable plaque. Vulnerable plaque (middle left) is characterized by high levels of
inflammatory cells, leading to increases in tissue factor (TF), matrix metalloproteinase (MMP), and
reactive oxygen species (ROS). These factors degrade the fibrous cap and increase the likelihood of
thrombus formation. Apoptosis is common in endothelial and smooth muscle cells (SMCs) of vulnerable
plaque, decreasing stability and making blood-plaque interaction more probable. The stable plaque (middle
right) shows lower inflammatory cell response and increased SMC development, further strengthening the
cap that separates vessel intima from blood.129 Ktrans maps of LLSS and OSS regions (bottom) showed
significantly greater uptake kinetics at the 9-week timepoint in cuffed artery compared with the control
artery.
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3.3.3 Differential nanoparticle accumulation based on plaque phenotype.
Ktrans values from the cuffed artery at the 9-week timepoint were compared with
plaque burden (PB) and lipid concentration (LC) values calculated from corresponding
histological sections. Data were separated based on hemodynamic region, OSS and
LLSS. Assessment of correlation using linear regression showed a negative correlation
between OSS Ktrans and PB (p < 0.01), and a positive correlation between LLSS Ktrans and
PB (p < 0.05). No significant correlation was observed between Ktrans and LC in OSS or
LLSS regions.

Figure 3.4 Correlation plots of Ktrans with PB (bottom) and LC (top) in both OSS (left) and LLSS (right)
regions. No correlation was observed between Ktrans and LC, nor between Ktrans and PB in either region.
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3.4 Discussion

Gd-based small molecule contrast agents (CAs) are commonly used in clinical

settings to evaluate vascular permeability with DCE-MRI.121 Concerns over toxicity and
mediocre contrast enhancement have inspired the development of paramagnetic NPbased CAs often utilizing iron oxide or lanthanide series ions, like Gd.49,130 However, for
these NPs to be useful in DCE-MRI, they must provide sufficient T1 contrast enhancing
properties. We have recently extended the use of DCE-MRI to assess vascular
permeability kinetics of NPs in the brain.128 Here, we use this same imaging technique to
determine accumulation kinetics of NPs across atherosclerotic plaques. Contrastenhancing FA-Gd NPs were synthesized for use in DCE-MRI and conjugated with
fluorescent probe AF647 for ex vivo histological imaging to validate accumulation and
assess cellular localization. FA-Gd synthesis resulted in a small core size, mean diameter
measured as 4.5 nm, with an increase surface area-to-volume ratio compared with larger
NPs, which promotes interactions between the Gd core and surrounding H2O molecules,
thereby increasing T1 effects.131
The FA coating, which was verified by FT-IR, functions as a surface coating38
and increases colloidal stability. Surface-bound FA draws H2O nearer to the core by
increasing hydrophilicity and further increases T1 effects.132,133 Enhancement of colloidal
stability is also provided by the large negative zeta potential, -40.5 mV, helping to
prevent aggregation and adsorption of negatively-charged serum proteins.134 The
physicochemical parameters present in FA-Gd here served to ensure strong T1enhancement and stability in blood. Another advantage of NP-based CAs is
physicochemical customizability. NP synthesis can be altered to manipulate
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physicochemical properties and in combination with uptake assessment, properties can be
controlled to maximize accumulation. Though FA-Gd in this work was solely diagnostic,
understanding the role NP properties have in uptake will be essential to improving
therapeutic effectiveness in the design of future NP-based therapeutics.
No difference in NP accumulation was observed between either plaque phenotype
and the control vessel at week 5. At week 9, however, a significant difference was
detected between both plaque phenotypes and the control vessel, an increase in NP
accumulation with plaque development. Previous work has suggested NP uptake into
atherosclerotic plaques in mice takes place primarily across disrupted macrovascular
endothelium.135 Though neovascularization into the plaque from the adventitia has been
noted in human studies,136,137 work in mice has shown limited connection between plaque
interior and adventitial microvasculature.138 The observed difference in uptake kinetics
then is likely due to differences in endothelial disruption along the lumen.
Past investigation into endothelial disruption over plaque lifetime has had
confounding results, with Phinikaridou et al.139 showing widening endothelial gaps with
plaque development, while Beldman et al. 135 showed endothelial stabilization with
plaque development. These studies observed a different ApoE-/- mouse model at different
stages in plaque development, with final timepoints at 12-weeks, complicating
comparison with the 9-week final timepoint in this work. The increases in accumulation
and retention seen at week 9 suggest increased endothelial disruption with plaque
development, in line with Phinikaridou. Beldman et al.135 utilized NPs with a
hydrodynamic diameter (HD) of 100 nm, while Phinikaridou et al.139 used a smaller
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albumin-Gd conjugate more similar in size to FA-Gd. The differing HDs between studies
may explain the observed differences in uptake kinetics, as NP studies of traumatic brain
injury53,128 and cancer18,140 have shown differing uptake with HD.
No difference in uptake was seen between the two plaque phenotypes and
comparing Ktrans with LC or PB showed no significant correlation. This would seem to
indicate a lack of direct relationship between PB, LC and degree of endothelial
disruption, though from comparing control and cuffed arteries we see increased
endothelial disruption within the plaque. Some of the lack of difference may be explained
by the similarity of PB and LC between the two plaque phenotypes. Despite the
physiological differences between the two phenotypes (Figure 3.3) there was no
difference in correlation detected. The physiology of the OSS plaque, thick fibrous cap
and smooth muscle cell (SMC) recruitment, limits blood-plaque interactions, while that
of the LLSS plaque, thin fibrous cap and SMC apoptosis, results in an increased
likelihood of blood-plaque interactions and thrombogenesis. Though biological outcomes
differ between the two phenotypes, no differences were seen in terms of NP
accumulation, this may be related to the small HD of the FA-Gd utilized in this work.
The differences seen in NP accumulation and retention between cuffed and control
vessels may also be related to hemodynamic differences, but the lack of difference in
accumulation at the 5-week timepoint suggests hemodynamic differences alone do not
account for the observed differential uptake at week 9. NPs with different HD or those
specifically targeted to components of plaque, like CD146 on foam cells,141 more
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numerous in vulnerable plaques, may result in distinct uptake profiles between the two
plaque phenotypes.

3.5 Conclusion

NPs may offer an improved, more specific strategy for treating atherosclerosis.

Therefore, better understanding how plaque characteristics affect NP accumulation and
retention is necessary to expedite NP development. Using a cuffed mouse model of
atherosclerosis that presents with reproducible stable and vulnerable advanced plaques
downstream and upstream of the cuff, respectively, we found that accumulation and
retention kinetics of FA-Gd NPs are independent of the specific morphology of advanced
plaque, but dependent on plaque development. FA-Gd accumulation was detected within
both plaque phenotypes at 9 weeks and supports the further investigation of NP-based
therapeutics to take advantage of endothelial disruption and more effectively deliver
therapy to diseased vessels. Comparing our results with those of previous studies
suggests the change in uptake seen with plaque development may also depend upon NP
HD. These finding will help support future NP development for improved therapeutic
delivery to atherosclerotic lesions, which should focus on both optimizing HD for uptake
and active targeting strategies to maximize accumulation and retention within the plaque.
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CHAPTER 4: CONCLUSIONS AND FUTURE WORK
4.1 Summary and conclusions

From before the proposal of the EPR effect up through the present there has been

an enormous amount of time and effort spent investigating NPs for application in cancer
and other condition involving disrupted endothelium, yet clinical success remains elusive.
Despite the increased understanding of NP behavior in numerous pre-clinical models as
well as in humans, the nano-bio interactions that govern biological responses are still
misunderstood. To aid in understanding the role NP physicochemical properties have on
uptake, a DCE-MRI acquisition and processing procedure was developed and tested in
two different animal models with contrast-enhancing NPs.
In a CCI mouse model of TBI uptake of three different NPs was compared with
that of Gd-DTPA, a clinically approved small molecule CA. Uptake assessment based on
Ktrans, calculated using a reference region kinetic model, showed much greater sensitivity
than final concentration maps when comparing BBB permeability in the focal injury with
that of the undamaged contralateral hemisphere. PLGA and Pro-NPs as well as GdDTPA showed significantly higher Ktrans in the focal injury than the contralateral
hemisphere, and Cj-1 was limited by sample availability. Ktrans mapping highlighted an
interactive effect on uptake between post-injury injection time and NP properties,
showing significantly greater uptake of PLGA NPs when injected 3 h post-injury, while
showing no time dependence using Gd-DTPA. The difference in time dependence seen
between PLGA and Gd-DTPA illustrates the role that CA properties have on Ktrans,
though much of its previous use in research has been to describe tumor status. The
interaction between injection time and physicochemical properties suggests that NP
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properties could be selected to exhibit maximum accumulation at later timepoints postinjury, as immediate administration post-injury is unrealistic in clinical settings. Ktrans
mapping also showed uptake PLGA NPs at 48 h post-injury, indicating continued BBB
disruption. Of key importance was the use of Ktrans to detect differential uptake based on
CA physicochemical properties.
A carotid artery cuff mouse model of atherosclerosis showed significantly greater
uptake in both LLSS (vulnerable) and OSS (stable) plaque phenotypes compared with the
contralateral unmodified artery in fully developed plaques. Assessment of NP
accumulation used Ktrans, quantified using the Patlak model,73 to compare plaque
phenotypes using a folic acid-coated Gd NP. Accumulation was independent of plaque
phenotype, but dependent upon plaque development. Comparison with the literature
suggests a possible interaction between NP physicochemical properties and
accumulation, as previous studies have shown either increasing endothelial stability135 or
disruption139 with plaque development, but used CAs with drastically different properties.
Importantly, Ktrans mapping showed a significant difference between diseased and control
vessels, corroborating previous results that show increased endothelial disruption in
atherogenic vascular regions.

4.2 Suggested future work

The purpose of this work was not to arrive at optimal physicochemical properties

for NP uptake in any specific application, but to establish and test a DCE-MRI method
for uptake assessment. Based on the work presented here, future work should be carried
out using Ktrans mapping to compare differential uptake kinetics between NPs based on
physicochemical differences in a systematic manner. In TBI, previous work has shown
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higher NP uptake with decreasing HD using fluorescent NPs, this work however
compared only one timepoint per animal and compared NPs per region, complicating
comparison of differently sized NPs. Comparing uptake kinetics by size using Ktrans
mapping will simplify comparison putting everything on the same scale and may more
clearly describe an optimal size range for uptake similar to results seen in tumors. Uptake
kinetic comparison should also be used to assess targeting ligand conjugation effects in
specific applications. In TBI, for example, uptake related to specific BBB peptide targets
can be assessed and compared, while future suggested targets can be tested and
meaningfully compared with previous studies.
In atherosclerosis, uptake kinetics and endothelial integrity should be assessed at
timepoints between 5 and 9 weeks, and perhaps at even earlier timepoints to determine
how endothelial disruption develops following cuff implantation. Based on confounding
results between previous studies, an assessment of atherosclerotic plaque uptake based on
plaque phenotype and NP size may help to illuminate the changes occurring in the
luminal endothelium over the lifetime of the plaque. NP design should then be modified
to optimize physicochemical properties for plaque accumulation in a therapeutic particle
and efficacy compared with current treatment options.
Continued research into particle property effects on nano-bio interactions is
essential to the development of the next generation of nanotheranostics. Understanding
the effects of size, surface charge, shape, targeting ligands, elemental composition, etc.
on biological outcomes will inform more effective NP design. With the thoughtful design
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enabled by an improved understanding, promising pre-clinical developments can be more
readily translated into clinical improvements.
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